Artificial pancreas

Automatic and semi-automatic regulation of glycemia in type 1 diabetes mellitus patients is a long standing control challenge. The main drawback of both open- and closed-loop therapies is the excess of insulin delivered after the meals, which in many cases produces severe hypoglycemia events. Intra-patient variability, delays and lack of accurate on-line blood glucose level measurement impose severe limitations to the achievable performance. We develop control algorithms to reduce the events of hypoglycemia without increasing the risk of hyperglycemia.